Ocular Therapeutix™ to Participate at Three Upcoming Investor Conferences
November 08 2022 - 8:00AM
Business Wire
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical
company focused on the formulation, development, and
commercialization of innovative therapies for diseases and
conditions of the eye, today announced that it will participate at
the following conferences:
Jefferies London Healthcare Conference Fireside Chat
Date: Wednesday November 16, 2022 Fireside Chat Time: 2:05 PM GMT
Location: Waldorf Hilton, London, UK
BTIG Virtual Ophthalmology Day 2022 Fireside Chat Date:
Tuesday, November 29, 2022 Fireside Chat Time: 8:30 AM EST
Piper Sandler 34th Annual Healthcare Conference Fireside
Chat Date: Wednesday November 30, 2022 Fireside Chat Time: 12:00 PM
EST Location: Lotte New York Palace, New York, NY
Management will be available throughout the day for investor
meetings at all three conferences. If you plan to attend at least
one of the conferences and are interested in meeting with
management, please contact your Jefferies, BTIG or Piper Sandler
representative.
A live webcast of the fireside chats at the Jefferies London
Healthcare Conference and Piper Sandler 34th Annual Healthcare
Conference can be accessed by visiting the Investors section of the
Company’s website at investors.ocutx.com. It will also be available
for replay for 90 days.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company focused
on the formulation, development, and commercialization of
innovative therapies for diseases and conditions of the eye using
its proprietary bioresorbable hydrogel-based formulation
technology. Ocular Therapeutix’s first commercial drug product,
DEXTENZA®, is an FDA-approved corticosteroid for the treatment of
ocular inflammation and pain following ophthalmic surgery and
ocular itching associated with allergic conjunctivitis. Ocular
Therapeutix’s earlier stage development assets include: OTX-TKI
(axitinib intravitreal implant), currently in Phase 1 clinical
trials for the treatment of wet AMD and other retinal diseases;
OTX-TIC (travoprost intracameral implant), currently in a Phase 2
clinical trial for the treatment of primary open-angle glaucoma or
ocular hypertension; and OTX-CSI (cyclosporine intracanalicular
insert) for the chronic treatment of dry eye disease and OTX-DED
(dexamethasone intracanalicular insert) for the short-term
treatment of the signs and symptoms of dry eye disease, both of
which have completed Phase 2 clinical trials.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221108005353/en/
Investors Ocular Therapeutix Donald Notman Chief
Financial Officer dnotman@ocutx.com
or
ICR Westwicke Chris Brinzey, 339-970-2843 Managing Director
chris.brinzey@westwicke.com
Media Ocular Therapeutix Scott Corning Senior Vice
President, Commercial scorning@ocutx.com
Ocular Therapeutix (NASDAQ:OCUL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ocular Therapeutix (NASDAQ:OCUL)
Historical Stock Chart
From Apr 2023 to Apr 2024